Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: vulink aj. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
Baltussen JC, Mooijaart SP, Vulink AJE, Houtsma D, Van der Deure WM, Westerman EM, Oosterkamp HM, Spierings LEAMM, van den Bos F, de Glas NA, Portielje JEA. Baltussen JC, et al. Among authors: vulink aje. Breast Cancer Res Treat. 2024 Apr 16. doi: 10.1007/s10549-024-07312-y. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38627318
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
Vliek S, Hilbers FS, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, Lips EH, Mulder L, Kayembe MT, Loo CE, Russell NS, Vrancken Peeters MTFD, Holtkamp MJ, Schot M, Baars JW, Honkoop AH, Vulink AJE, Imholz ALT, Vrijaldenhoven S, van den Berkmortel FWPJ, Meerum Terwogt JM, Schrama JG, Kuijer P, Kroep JR, van der Padt-Pruijsten A, Wesseling J, Sonke GS, Gilhuijs KGA, Jager A, Nederlof P, Linn SC. Vliek S, et al. Among authors: vulink aje. NPJ Breast Cancer. 2023 Sep 9;9(1):75. doi: 10.1038/s41523-023-00580-9. NPJ Breast Cancer. 2023. PMID: 37689749 Free PMC article.
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, Lopez-Yurda M, Swijnenburg RJ, Punt CJA; Dutch Colorectal Cancer Study Group. Bond MJG, et al. Lancet Oncol. 2023 Jul;24(7):757-771. doi: 10.1016/S1470-2045(23)00219-X. Epub 2023 Jun 14. Lancet Oncol. 2023. PMID: 37329889 Clinical Trial.
Mental health outcomes in older breast cancer survivors: Five-year follow-up from the CLIMB study.
Lemij AA, de Glas NA, Derks MGM, Linthorst-Niers EMH, Guicherit OR, van der Pol CC, Lans TE, van Dalen T, Vulink AJE, Merkus JWS, van Gerven L, van den Bos F, Rius Ottenheim N, Liefers GJ, Portielje JEA. Lemij AA, et al. Among authors: vulink aje. Eur J Cancer. 2023 Jul;187:87-95. doi: 10.1016/j.ejca.2023.04.001. Epub 2023 Apr 5. Eur J Cancer. 2023. PMID: 37130464 Free article.
Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer.
Lugtenberg RT, de Groot S, Houtsma D, Dezentjé VO, Vulink AJE, Fischer MJ, Portielje JEA, van der Hoeven JJM, Gelderblom H, Pijl H, Kroep JR. Lugtenberg RT, et al. Among authors: vulink aje. Cancers (Basel). 2023 Mar 9;15(6):1691. doi: 10.3390/cancers15061691. Cancers (Basel). 2023. PMID: 36980577 Free PMC article.
Physical Function and Physical Activity in Older Breast Cancer Survivors: 5-Year Follow-Up from the Climb Every Mountain Study.
Lemij AA, Liefers GJ, Derks MGM, Bastiaannet E, Fiocco M, Lans TE, van der Pol CC, Vulink AJE, van Gerven L, Guicherit OR, Linthorst-Niers EMH, Merkus JWS, van Dalen T, Portielje JEA, de Glas NA. Lemij AA, et al. Among authors: vulink aje. Oncologist. 2023 Jun 2;28(6):e317-e323. doi: 10.1093/oncolo/oyad027. Oncologist. 2023. PMID: 36943287 Free PMC article.
Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study.
Baltussen JC, Derks MGM, Lemij AA, de Glas NA, Fiocco M, Linthorst-Niers EMH, Vulink AJE, van Gerven L, Guicherit OR, van Dalen T, Merkus JWS, Lans TE, van der Pol CC, Mooijaart SP, Portielje JEA, Liefers GJ. Baltussen JC, et al. Among authors: vulink aje. Eur J Cancer. 2023 May;185:1-10. doi: 10.1016/j.ejca.2023.02.008. Epub 2023 Feb 17. Eur J Cancer. 2023. PMID: 36933518 Free article.
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, de Vries N, Rosing H, Otten H, Vulink AJE, Desar IME, Imholz ALT, Gelderblom H, van Erp NP, Beijnen JH, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: vulink aje. Ann Oncol. 2022 Oct;33(10):1071-1082. doi: 10.1016/j.annonc.2022.06.010. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777707 Free article.
25 results